收费全文 | 3616996篇 |
免费 | 256088篇 |
国内免费 | 9473篇 |
耳鼻咽喉 | 48815篇 |
儿科学 | 119955篇 |
妇产科学 | 99375篇 |
基础医学 | 508261篇 |
口腔科学 | 102115篇 |
临床医学 | 331240篇 |
内科学 | 705178篇 |
皮肤病学 | 85351篇 |
神经病学 | 292699篇 |
特种医学 | 137171篇 |
外国民族医学 | 941篇 |
外科学 | 540149篇 |
综合类 | 77794篇 |
现状与发展 | 8篇 |
一般理论 | 1392篇 |
预防医学 | 276954篇 |
眼科学 | 83848篇 |
药学 | 264019篇 |
12篇 | |
中国医学 | 7987篇 |
肿瘤学 | 199293篇 |
2019年 | 28658篇 |
2018年 | 40853篇 |
2017年 | 31135篇 |
2016年 | 35431篇 |
2015年 | 40139篇 |
2014年 | 55554篇 |
2013年 | 83018篇 |
2012年 | 111903篇 |
2011年 | 118446篇 |
2010年 | 70931篇 |
2009年 | 67336篇 |
2008年 | 110297篇 |
2007年 | 117413篇 |
2006年 | 119031篇 |
2005年 | 114177篇 |
2004年 | 109866篇 |
2003年 | 105666篇 |
2002年 | 102062篇 |
2001年 | 175746篇 |
2000年 | 179882篇 |
1999年 | 151284篇 |
1998年 | 42990篇 |
1997年 | 37867篇 |
1996年 | 37993篇 |
1995年 | 36842篇 |
1994年 | 33680篇 |
1993年 | 31562篇 |
1992年 | 117089篇 |
1991年 | 112933篇 |
1990年 | 109310篇 |
1989年 | 105603篇 |
1988年 | 96564篇 |
1987年 | 94586篇 |
1986年 | 88801篇 |
1985年 | 84782篇 |
1984年 | 63205篇 |
1983年 | 53634篇 |
1982年 | 31459篇 |
1981年 | 28040篇 |
1979年 | 55909篇 |
1978年 | 39251篇 |
1977年 | 33402篇 |
1976年 | 31142篇 |
1975年 | 32956篇 |
1974年 | 39314篇 |
1973年 | 37577篇 |
1972年 | 35093篇 |
1971年 | 32572篇 |
1970年 | 30100篇 |
1969年 | 28767篇 |
Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献In order to offer early and accessible treatment for adolescents with depression, brief and effective treatments in adolescents’ everyday surroundings are needed. This randomized controlled trial studied the preliminary effectiveness, feasibility, and acceptability of interpersonal counseling (IPC) and brief psychosocial support (BPS) in school health and welfare services. The study was conducted in the 28 lower secondary schools of a large city in Southern Finland, randomized to provide either IPC or BPS. Help-seeking 12–16-year-old adolescents with mild-to-moderate depression, with and without comorbid anxiety, were included in the study. Fifty-five adolescents received either 6 weekly sessions of IPC or BPS and two follow-up sessions. Outcome measures included self- and clinician-rated measures of depression, global functioning, and psychological distress/well-being. To assess feasibility and acceptability of the treatments, adolescents’ and counselors’ treatment compliance and satisfaction with treatment were assessed. Both treatments were effective in reducing depressive disorders and improving adolescents’ overall functioning and well-being. At post-treatment, in both groups, over 50% of adolescents achieved recovery based on self-report and over 70% based on observer report. Effect sizes for change were medium or large in both groups at post-treatment and increased at 6-month follow-up. A trend indicating greater baseline symptom severity among adolescents treated in the IPC-providing schools was observed. Adolescents and counselors in both groups were satisfied with the treatment, and 89% of the adolescents completed the treatments and follow-ups. This trial suggests that both IPC and BPS are feasible, acceptable, and effective treatments for mild-to-moderate depression in the school setting. In addition, IPC seems effective even if comorbid anxiety exists. Our study shows that brief, structured interventions, such as IPC and BPS, are beneficial in treating mild-to-moderate depression in school settings and can be administered by professionals working at school.
Trial registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT03001245.
相似文献